Cancer Epidemiology, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
BMJ Open. 2022 Feb 23;12(2):e054091. doi: 10.1136/bmjopen-2021-054091.
Advanced ovarian cancer is a severe disease with major side effects caused by peritoneal carcinomatosis, ascites and gastrointestinal involvement as well as exhaustive treatment like debulking surgery and combination chemotherapy. Two most frequently reported side effects are muscle wasting and malnutrition, leading to frailty, decreased health-related quality of life (HRQoL) and cancer-related fatigue (CRF). As muscle wasting and malnutrition often commence during first-line chemotherapy and develop progressively into a refractory state, an early intervention is warranted. This pilot study aimed to evaluate the safety and acceptance of a combined exercise and nutrition intervention during and after first-line chemotherapy.
The pilot study was conducted as a monocentric 1:1 randomised controlled trial (RCT) with an intervention group (IG) and a control group (CG). Participants were divided by chance into IG or CG. Information on group allocation was conveyed to the study coordinator responsible for making an appointment with the patients for the baseline assessment as well as the physiotherapist and nutritionist responsible for the intervention and outcome assessment in both groups.
Eligibility criteria included women ≥18 years of age, diagnosed with ovarian cancer, tubal cancer or peritoneal cancer and primary or interval debulking, scheduled but not started adjuvant or neoadjuvant chemotherapy and sufficient German-language skills.
The IG received a 12-month exercise and nutrition programme, the CG continued to follow usual care.
Primary outcomes were recruitment rate, adherence to intervention, completion rate and adverse events. In addition, in-person assessments (eg, HRQoL, CRF, muscle quality and function and dietary intake and quality) were conducted at baseline (T0, before chemotherapy), week 9 (T1, mid-chemotherapy), week 19 (T2, after completion of chemotherapy) and after 12 months of intervention (T3).
Of 60 eligible patients, 15 patients signed informed consent (recruitment rate=25.0%) and were randomised into IG (n=8) and CG (n=7). Eleven participants completed the study (completion rate, 73.3%), one patient dropped out due to loss of interest, one due to poor health, one was lost to follow-up and one patient died.
The BENITA (Bewegungs- und Ernährungsintervention bei Ovarialkrebs) study demonstrated the safety and acceptance of an exercise and nutrition intervention integrated into first-line therapy and follow-up care of ovarian cancer. A large multicentre RCT is planned to investigate the effectiveness of the intervention on HRQoL, CRF and survival and to establish means of implementation into oncology guidelines and clinic routine.
DRKS00013231.
晚期卵巢癌是一种严重的疾病,会导致腹膜癌病、腹水和胃肠道受累等严重副作用,并且需要进行减瘤手术和联合化疗等大量治疗。最常报告的两种副作用是肌肉减少症和营养不良,导致虚弱、健康相关生活质量(HRQoL)下降和癌症相关疲劳(CRF)。由于肌肉减少症和营养不良通常在一线化疗期间开始,并逐渐发展为难治性状态,因此需要早期干预。本研究旨在评估在一线化疗期间和之后联合运动和营养干预的安全性和可接受性。
该研究为单中心 1:1 随机对照试验(RCT),设有干预组(IG)和对照组(CG)。参与者通过机会分配进入 IG 或 CG。组分配信息传达给负责为基线评估预约患者的研究协调员,以及负责两组干预和结局评估的物理治疗师和营养师。
纳入标准包括年龄≥18 岁、诊断为卵巢癌、输卵管癌或腹膜癌、原发性或间隔性减瘤术、计划但尚未开始辅助或新辅助化疗,且具备足够的德语技能。
IG 接受为期 12 个月的运动和营养方案,CG 继续接受常规护理。
主要结局指标为招募率、干预依从性、完成率和不良事件。此外,还在基线(T0,化疗前)、第 9 周(T1,化疗中期)、第 19 周(T2,化疗结束后)和干预 12 个月后(T3)进行了面对面评估(例如,HRQoL、CRF、肌肉质量和功能、饮食摄入和质量)。
在 60 名符合条件的患者中,有 15 名患者签署了知情同意书(招募率=25.0%),并被随机分配到 IG(n=8)和 CG(n=7)。11 名参与者完成了研究(完成率为 73.3%),1 名患者因失去兴趣而退出,1 名患者因健康状况不佳而退出,1 名患者失访,1 名患者死亡。
BENITA(卵巢癌运动和营养干预)研究表明,将运动和营养干预纳入一线治疗和卵巢癌随访护理中是安全且可接受的。计划开展一项大型多中心 RCT,以调查该干预措施对 HRQoL、CRF 和生存率的有效性,并确定将其纳入肿瘤学指南和临床常规的实施方法。
DRKS00013231。